FDA approves iPad-based blood loss monitor

The FDA gave de novo approval to Gauss Surgical's Triton Fluid Management System blood loss monitor. The approval is significant because the device uses an iPad camera and cloud analytics. The company intended to file a 510(k) but instead spent 15 months going through the de novo approval process because the FDA could not find a substantially equivalent device. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.